Skip to main content
Top

19-09-2017 | Hypertension | Practical approach | Article

A Practical Approach to Hypertension Management in Diabetes

Journal: Diabetes Therapy

Author: Altamash Shaikh

Publisher: Springer Healthcare

Abstract

Hypertension is one of the most important comorbidities of diabetes, contributing significantly to death and disability and leads to macrovascular and microvascular complications. When assessing the medical priorities for patients with diabetes, treating hypertension should be a primary consideration. Practical approaches to hypertension in diabetes, including individualized targets are discussed, as per stage and complication of diabetes, according to current studies and guidelines. Angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARBs) are the most effective drugs for treating hypertension in diabetes, in the absence of contraindications. Calcium antagonists or diuretics are acceptable as second-line agents. Once the target is achieved, antihypertensive drugs should be continued. Newer antidiabetes medications such as sodium glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1-RA), and dipeptidyl peptidase-4 inhibitors (DPP4i) have antihypertensive properties and may assist in treatment decision-making.
Literature
1.
Wang CCL, Reusch JEB. Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survival. Am J Cardiol. 2012;110:58B–68B. doi:10.​1016/​j.​amjcard.​2012.​08.​036.CrossRefPubMedPubMedCentral
2.
Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep. 2012;14:160–6. doi:10.​1007/​s11883-012-0227-2.CrossRefPubMedPubMedCentral
3.
Banach M, Aronow WS. Blood pressure J-curve: current concepts. Curr Hypertens Rep. 2012;14:556–66. doi:10.​1007/​s11906-012-0314-3.CrossRefPubMedPubMedCentral
4.
American Diabetes Association. Standards of Medical care in diabetes – 2017. Diabetes Care. 2017;40(supp 1):1–142.
5.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.CrossRefPubMedCentral
6.
Dahlof B, Server PS, Poulter NR, et al. Prevention of cardiovas- cular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.CrossRefPubMed
7.
Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40.CrossRefPubMed
8.
Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens. 2003;16(11 Pt 2):41S–5S.CrossRefPubMed
9.
Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol. 2005;42(Suppl 1):S17–25.CrossRefPubMed
10.
Haffner SM, Lehto S, Rönnemaa T, Pyörölä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.CrossRefPubMed
11.
Leese GP, Savage MW, Chattington PD, Vora JP. The diabetic patient with hypertension. Postgrad Med J. 1996;72:263–8.CrossRefPubMedPubMedCentral
12.
Jesmin J, Rashid MS, Jamil H, et al. Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension. BMC Med Genom. 2010;3:45.CrossRef
13.
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clini Diabetes. 2008;26(2):77–82.CrossRef
14.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treat- ment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.CrossRefPubMed
15.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–64.CrossRef
16.
Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004;6(3):116–25.CrossRef
17.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.CrossRefPubMed
18.
Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.CrossRefPubMed
19.
ESH/ESC Task Force for the Management of Arterial Hypertension. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens. 2013;1(10):1925–38.
20.
James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefPubMed
21.
Daskalopoulou SS, Rabi D, Zamke KB, CHEP for the Canadian Hypertension Education Program. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2015;31(5):549–69.CrossRefPubMed
22.
World Health Organization. A global brief on hypertension. Geneva: WHO; 2013.
23.
International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: IDF; 2012.
24.
Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37(4):253–390.CrossRefPubMed
25.
Association of Physicians of India. Indian guidelines on hypertension (IGH) - III. 2013. J Assoc Physicians India. 2013;61(2 Suppl):6–36.
26.
Rosendorff CLD, Allison M, et al. AHA/ASH American Heart Association, American College of Cardiology, American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015;131(19):e435–70.CrossRefPubMed
27.
Weber MA, Schiffrin S, White WB, et al. ASH/ISH clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3–15.CrossRefPubMed
28.
PA, Sarafidis PA. Epidemiology of resistant hypertension. J Clin Hypertens (Greenwich, Conn). 2011;362:1575–85. doi:10.​1056/​NEJMoa1001286.
29.
Hirakawa Y, Arima H, Webster R, et al. Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes. J Hypertens. 2016;34(4):781–7.CrossRefPubMed
30.
SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRef
31.
ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. doi:10.​1056/​NEJMoa1001286.CrossRef
32.
Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. doi:10.​1136/​bmj.​i717.CrossRefPubMedPubMedCentral
33.
Adamsson Eryd S, Gudbjörnsdottir S, Manhem K, et al. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ. 2016;354:i4070.CrossRefPubMedPubMedCentral
34.
Currie CJ, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35:1279–84. doi:10.​2337/​dc11-1277.CrossRefPubMedPubMedCentral
35.
Shaikh A, et al. Family therapy in diabetes mellitus. Indian Endocrinol Metab. 2013;17(Suppl 1):S292–4.
36.
Liu J, Huang S, Yang X, Liu S, Cai L, Jiao J. Investigation and analysis on the implementation of family therapy for elderly patients with hypertension in community. J Resid Sci Technol. 2016;13(8). doi:10.​12783/​issn.​1544-8053/​13/​8/​386.
37.
Machado AP, et al. Educational strategies for the prevention of diabetes, hypertension, and obesity. Rev Assoc Med Bras. 2016;1992(62):800–8. doi:10.​1590/​1806-9282.​62.​08.​800.CrossRef
38.
Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:4891.CrossRef
39.
Pai PY, Muo C, Sung FC, Ho HC, Lee YT. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes—a real-world population study in Taiwan. Int J Cardiol. 2016;215:114–9.CrossRefPubMed
40.
Jindal A, Naqvi SH, Waqar Salam M, Sowers JR. In: De Groot LJ et al, editor. Hypertension in diabetes. South Dartmouth: Endotext. 2000.
41.
Kurtz TW, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133–43. doi:10.​2147/​VHRM.​S22595.CrossRefPubMedPubMedCentral
42.
Phillips RA. Current and future treatment of hypertension in the SPRINT era. Methodist DeBakey Cardiovasc J. 2015;11:206–13. doi:10.​14797/​mdcj-11-4-206.CrossRefPubMedPubMedCentral
43.
Nilsson PM. Target blood pressure in diabetes patients with hypertension—what is the accumulated evidence in 2011? J Zhejiang Univ Sci B. 2011;12:611–23. doi:10.​1631/​jzus.​B1101001.CrossRefPubMedPubMedCentral
44.
The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JNC 7. NIH Publication, No. 04-5230. 2004.
45.
Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J. 2011;32:2739–47. doi:10.​1093/​eurheartj/​ehr253.CrossRefPubMedPubMedCentral
46.
Bakris G, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–94.CrossRefPubMed
47.
Kalra S. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review. Cardiol Ther. 2016;5:161–8. doi:10.​1007/​s40119-016-0069-z.CrossRefPubMedPubMedCentral
48.
Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267–82.CrossRefPubMedPubMedCentral
49.
Hach T, Gerich J, Salsali A, Kim G, Hantel S, Woerle HJ, et al. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Diabetol Stoffwechs. 2014;9:142.CrossRef
50.
Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737–49. doi:10.​1111/​dom.​12085.CrossRefPubMed
51.
Marso SP, Daniel G, Brown-Frandsen K, et al. Liraglutide and cardiovascular Outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.CrossRefPubMedPubMedCentral
52.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. NEJM. 2016;375:1834–44.CrossRefPubMed
53.
Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5):592–8.CrossRefPubMed
54.
Ogawa S, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223:133–5. doi:10.​1620/​tjem.​223.​133.CrossRefPubMed
55.
Yuasa S, Sato K, Furuki T, et al. Primary care-based investigation of the effect of sitagliptin on blood pressure in hypertensive patients with type 2 diabetes. J Clin Med Res. doi:10.​14740/​jocmr2820w.
56.
Cosenso-Martin LN, Giollo-Junior LT, Vilela-Martin JF. DPP-4 inhibitor reduces central blood pressure in a diabetic and hypertensive patient: a case report. Medicine. 2015;94:e1068. doi:10.​1097/​md.​0000000000001068​.CrossRefPubMedPubMedCentral
57.
Marney AKS, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56(4):728–33.CrossRefPubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »